Examiner O'Neill Marisol A

1633-ONEILL-MARISOL-A

Employment Information

Art Unit:1633 — Drug, bio-affecting and body treating compositions
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 435 — Chemistry: molecular biology and microbiology
424 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
800 — Multicellular living organisms and unmodified parts thereof and related processes
Phone:(571) 272-2490
Email:None
Location:None
Title:Pat Examnr (Biology)
Service:1 years
Grade:GS-09

Grant Rate and Difficulty Ranking

3-Year Grant rate: 0% over 6 cases
Difficulty: Not enough data to rank
Difficulty Percentile:

With Examiner O'Neill, you have a 0% chance of getting an issued patent by 3 years after the first office action.

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner O'Neill, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1633

Examiner O'Neill's grant rate is lower than that of Art Unit 1633 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner O'Neill 2.0
Art Unit 1633 2.0

Interview Benefit

Grant Rate without Interview

Examiner O'Neill has granted 0 of 6 cases without any applicant-requested interviews for a grant rate of 0%.

Grant Rate with Interview

Examiner O'Neill has granted 0 of 0 cases with at least one applicant-requested interview for a grant rate of 0%.

Interview Benefit

With Examiner O'Neill, conducting an interview increases your chance of getting a patent granted by 100%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17957677 Method For Treating Pleural Effusion Rejection information available with a Premium Stats subscription. See our pricing. Patented View
17767426 Modified Endonucleases And Related Methods Abandoned View
17756618 Metabolism Guides Definitive Lineage Specification During Endothelial To Hematopoietic Transition Abandoned View
18072718 Methods For Creating Edible Scaffolding Using Chilean Seaweed (Cochayuyo) Abandoned View
17785816 Codon-Optimized Cas9 Endonuclease Encoding Polynucleotide Abandoned View
17799948 Maturation Of Spermatogonial Cells In Vitro Bt Growth Factors And Hormones Abandoned View
17918105 Peptides For Inducing Differentiation Abandoned View
18048267 Treatment Of Liver Cancer Or Liver Fibrosis Abandoned View
17507324 Methods And Compositions For Nucleic Acid-Guided Nuclease Cell Targeting Screen Abandoned View
17869943 Irf Modulator-Expressing Oncolytic Viruses For Treating Cancer Abandoned View
17795250 Methods And Systems For Producing Aav Particles Abandoned View
17761989 Bcma-Targeted Antibody And Chimeric Antigen Receptor Abandoned View
17635358 Crispr Genome Editing With Cell Surface Display To Produce Homozygously Edited Eukaryotic Cells Abandoned View
17553530 Method For The Generation Of A Protein Expressing Cell By Targeted Integration Using Cre Mrna Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.

Loading...